2021 Rheumatology Year in Review: New FDA Approvals and Indications, Biologics for Lupus & GCA, Hydroxychloroquine, IL-23 Inhibitors and JAK Inhibitor Warnings | VuMedi

RheumNow

2021 Rheumatology Year in Review: New FDA Approvals and Indications, Biologics for Lupus & GCA, Hydroxychloroquine, IL-23 Inhibitors and JAK Inhibitor Warnings

By RheumNow FEATURING John J. Cush

By RheumNow FEATURING John J. Cush

279 views

January 14, 2022

0 Comments

Login to view comments. Click here to Login